Klinická farmakologie a farmacie – 2/2021

www.klinickafarmakologie.cz / Klin Farmakol Farm 2021; 35(2): 78–87 / KLINICKÁ FARMAKOLOGIE A FARMACIE 87 PŘEHLEDOVÉ ČLÁNKY Lékové interakce antiepileptik Část 2 – interakce s léky z jiných indikačních skupin 13. Kacířová I, Grudmann M. Význam interakcí antiepileptik v rutinní klinické praxi. Klin Farmakol Farm. 2021; 35: 19–23. 14. Battino D, Estienne M, Avanzini G. Clinical pharmacokine- tics of antiepileptic drugs in paediatric patients. Part I. Phe- nobarbital, primidone, valproic acid, ethosuximide and me- suximide. Clin Pharmacokinet. 1995; 29: 257–286. 15. Hess L. Pethidin slaví 70 let. Remedia 2009; 19: 213–214. 16. Kut H. Phenytoin Interactions with other drugs: clinical aspects. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepi- leptic Drugs. New York: Raven Press 1995; 315–328. 17. Levy RH, Wurgen CJ. Carbamazepine. Interactions with other drugs. In Levy RH, Mattson RH, Meldrum BS, eds. Antie- pileptic Drugs. New York: Raven Press 1995; 543–554. 18. Oberndorfer S, Priribauer M, Marosi C, Lahrmann H, Hit- zenberger P, Grisold W. P450 enzyme inducing and non-en- zyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapyJ Neurooncol 2005; 72: 255–260. 19. Eckhardt K, Ammon S, Hofmann U et al. Gabapentin en- hances the analgesic effect of morphine in healthy volun- teers Anesth Analg. 2000; 91: 185–191. 20. Gélisse P, Hillaire-Buys D, Halaili E et al. Carbamazepine and clarithromycin: a clinically relevant drug interaction. Rev Neurol (Paris). 2007; 163: 1096–1099. 21. Faigle JW, Feldmann KF. Carbamazepine. Chemistry and biotransformation. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. New York: Raven Press 1995; 499–513. 22. ŠímaM, Hartinger J, Rulíšek J, Šachl R, Slanař O. Meropenem- -induced valproic acid elimination: A case report of clinically rele- vant drug interaction. PragueMedical Report 2017; 118: 105–109. 23. Khobrani MA, Dudley SW, Huckleberry YC, Kopp BJ, Biggs AD, French RNE, Shirazi FM, Erstad BL. Intentional use of car- bapenem antibiotics for valproic acid toxicity: A case report. J Clin Pharm Ther. 2018; 43: 723–725. 24. Thomas C, Priano J, Smith TL. Meropenem as an antido- te for intentional valproic acid overdose. Am J Emerg Med. 2020; 38: 690e1–690e2. 25. Gidal BE, Maganti R, Laurenza A, Yang Haichen Verbel DA, Schuck E, Ferry J. Effect of enzyme inhibition on perampa- nel pharmacokinetics: Why study design matters Epilepsy Res. 2017; 134: 41–48. 26. Manitpisitkul P, Curtin CR, Shalayda K, Wang S-S, Ford L, Heald D. Pharmacokinetic interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol. Clin Phar- macol Drug Dev 2014; 3: 378–387. 27. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Hen- ry EB, Harrison NJ, Schentag JJ. Ef fect of f luconazole on the disposition of phenytoin. Clin Pharmacol Ther. 1991; 49: 420–425. 28. Bullman J, Nicholls A, Van Landingham K, Fleck R, Vuong A, Miller J et al. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epi- lepsia 2011; 52: 1351–1358. 29. Chhun S, Versuyf C, Rizzo-Padoin N, Simoneau G, BEcquemont L, Peretti I et al. Gefitinib-phenytoin inte- raction is not correlated with the C-erythromycin bre- ath test in healthy male volunteers. Br J Clin Pharmacol. 2009; 68: 226–237. 30. May CA, Garnett WR, Small RE, Pellock RM. Effects of three antacids on the bioavailability of valproic acid. Clin Pharm. 1982; 1: 244–247.